跳至主要内容
临床试验/ACTRN12618001819213
ACTRN12618001819213招募中不适用

The role of [18F]FMISO PET in resolving Dotatate uptake in a doNUT-like pattern in neuroendocrine neoplasms

orthern Sydney Local Health District0 个研究点目标入组 10 人开始时间: 2018年11月8日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Diagnosis

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • 1) Patients 18 years of age or older with metastatic neuroendocrine neoplasm (NEN) and histological confirmation who have undergone PET scans at Royal North Shore Hospital
  • 2) Patients identified by the nuclear medicine physicians as having a lesion with 68Ga-DOTATATE PET (DOTA) avidity on the periphery but not the centre of the lesion (i.e. lack of avidity in the hole of the donut-like tumour).

排除标准

  • 1) Patients who have not received a PET scan at RNSH
  • 2) Patients without a histological diagnosis of metastatic NEN
  • 3) Inability to lie in a supine position on the PET scanning bed for 15 minutes;
  • 4) Subjects who required sedation for their baseline clinical PET scan;
  • 5) Renal failure requiring haemo- or peritoneal dialysis;
  • 6) Substance abuse, medical, psychological or social conditions that in the opinion of the investigator may interfere with the patient’s participation in the study or evaluation of the study results;

研究者

发起方
orthern Sydney Local Health District

相似试验